Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02005198 · ClinicalTrials.gov registry record
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 98
- Enrollment target
NCT02005198: Completed study, sponsored by Novo Nordisk A/S.
NCT02005198 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02005198 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
This study is conducted in the United States of America (USA). The aim of the study is to assess the minimal important difference (MID) of the TRIM-AGHD.
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-12 |
What the finished NCT02005198 record still lists
NCT02005198 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT02005198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02005198 about?
NCT02005198 is a clinical study titled "Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)". This study is conducted in the United States of America (USA). The aim of the study is to assess the minimal important difference (MID) of the TRIM-AGHD.
What is the current status of trial NCT02005198?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2014-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02005198?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT02005198?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia